Form 4: Atossa CEO Quay Boosts Stake with RSU and Option Grants

Atossa Therapeutics' President and CEO, Steven C. Quay, acquired 325,203 restricted stock units and 950,000 stock options on January 20, 2026, signaling increased insider ownership.

Summary

• Steven C. Quay, President & CEO and Director of Atossa Therapeutics, Inc. (ATOS), reported an acquisition of securities.
• On January 20, 2026, Quay acquired 325,203 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Common Stock each and will vest one year from the transaction date.
• Quay also acquired 950,000 Stock Options (right to buy) on January 20, 2026, with an exercise price of $0.603 per share.
• The options will vest on a quarterly basis over 24 months following January 20, 2026, contingent on Quay's continued service.
• The exercise price of $0.603 for the options represents the closing stock price on January 20, 2026.
• Following these transactions, Quay directly beneficially owns 339,101 shares of Common Stock and 950,000 Stock Options.
• Additionally, Quay indirectly beneficially owns 22,254 shares of Common Stock through Ensisheim Partners, LLC, which he co-owns with Dr. Shu-Chih Chen.

Sentiment

Score: 7

Explanation: The filing indicates a positive signal due to increased insider ownership and alignment of management's interests with shareholders through equity grants. This is a standard, positive event in executive compensation.

Positives

• The acquisition of a significant number of restricted stock units and stock options by the President and CEO indicates strong alignment of management's interests with shareholder value.
• Equity grants are a common incentive for executives, demonstrating confidence in the company's future performance.
• The options were granted at the closing stock price of $0.603 on the transaction date, suggesting a fair market valuation at the time of grant.

Future Outlook

The acquisition of equity awards by the CEO suggests a forward-looking commitment to the company's success and an expectation of future value creation, as the vesting of these awards is tied to continued service and potential stock price appreciation.

Management Comments

• Steven C. Quay, as President & CEO, acquired restricted stock units and stock options, aligning his future compensation with the company's performance.

Industry Context

Executive equity compensation, including restricted stock units and stock options, is a standard practice across various industries, particularly in biotechnology, to incentivize long-term performance and retain key leadership. This filing reflects a typical component of an executive's compensation package designed to align their financial interests with those of shareholders.

Related Party Transactions

• Steven C. Quay indirectly beneficially owns 22,254 shares of Common Stock through Ensisheim Partners, LLC, which is wholly owned by Quay and Dr. Shu-Chih Chen. Quay and Dr. Chen share voting and investment power over these securities.

Stakeholder Impact

• Shareholders: The increased equity ownership by the CEO aligns his financial incentives with the company's stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: The CEO's long-term commitment, as indicated by vesting schedules, can contribute to a stable leadership environment.

Next Steps

• The 325,203 Restricted Stock Units are scheduled to vest one year from January 20, 2026.
• The 950,000 Stock Options are scheduled to vest on a quarterly basis over 24 months following January 20, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant, which is generally a positive signal as it aligns the CEO's interests with shareholders. However, a single insider transaction, even by the CEO, typically does not warrant a 'buy' or 'strong buy' recommendation in isolation. It reinforces a 'hold' position for existing investors, indicating management's continued commitment, but does not provide new fundamental data to change a broader investment thesis.

Keywords

Atossa Therapeutics, ATOS, Steven C. Quay, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Executive Compensation, Biotechnology, Pharmaceuticals